Genitourinary Cancers | Specialty

Historic Perspective on Treatment of Bladder Cancer

March 16th 2017

Researcher Aims to Advance Immunotherapy Impact in Bladder Cancer

March 15th 2017

Arlene O. Siefker-Radtke, MD, discusses the exciting advances in the bladder cancer field, why researchers should move past PD-L1 as a biomarker, and what combinations can be expected to move through the pipeline next.

Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC Success

March 14th 2017

Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.

Researchers Aim to Further Enhance Value of RT in Prostate Cancer

March 14th 2017

Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer.

Dr. McDermott Discusses the Future of Immune Checkpoints in RCC

March 13th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.

Gomella Discusses Ongoing Progress With Genetic Testing in Prostate Cancer

March 11th 2017

Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.

Dr. Jonasch on Alternative Sunitinib Scheduling for mRCC

March 11th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).

Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer

March 10th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.

Dr. Linehan on Gene Mutations in Papillary Kidney Cancer

March 10th 2017

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses gene mutations in papillary kidney cancer.

"Richness of Choices" Available in Kidney Cancer, But Patient Selection Is Key

March 9th 2017

Eric Jonasch, MD, speaks on the evolving choices for patients with renal cell carcinoma in the first- and second-line settings, as well as the remaining challenges in the field.

Dr. McDermott on Lessons From the IMmotion150 Trial in RCC

March 8th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.

Petrylak Discusses Significance of Genetic Testing in Prostate Cancer

March 8th 2017

Daniel Petrylak, MD, discusses the significance of genetics in the future of prostate cancer care and highlights emerging treatments and challenges in the field.

Dr. Jonasch on First- and Second-line Options for Patients With RCC

March 8th 2017

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the advancements in the first- and second-line settings for treating patients with renal cell carcinoma (RCC). Jonasch shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Expert Discusses Promise of Immunotherapy in Genitourinary Cancers

March 8th 2017

Charles Drake, MD, PhD, discusses pairing immunotherapy with chemotherapy, the efficacy of current immunotherapy agents, and the future use of immunotherapy in the treatment of genitourinary cancers.

Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer

March 8th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the future of durvalumab in the treatment of bladder cancer.

Choueiri Discusses Papillary RCC, Other Developments in Kidney Cancer

March 7th 2017

Toni Choueiri, MD, discusses a study of the MET inhibitor savolitinib in papillary renal cell cancer as well as other exciting findings in kidney cancer.

Dr. Febbo Explains the Oncotype DX Genomic Prostate Score

March 7th 2017

Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.

A Call to Educate

March 4th 2017

Raoul S. Concepcion, MD, calls for increased oncology education and information sharing among the urology community across the globe, as urologists play a critical role in delivering and managing cancer treatment.

Dr. Drake on Immunotherapy Side Effects in Genitourinary Cancers

March 4th 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.

Vaccine Shows Promise in Renal Cell Carcinoma

March 3rd 2017

Hans J. Hammers, MD, PhD, discusses early promising data for HyperAcute Renal immunotherapy in renal cell carcinoma and the overall potential for vaccines in the field.